

## DOCTORAL THESIS

### Elucidation of anticancer efficacy of ent-kaurane diterpenes through structure-activity relationship and mechanism of action studies

Sarwar, Md Shahid

*Date of Award:*  
2019

[Link to publication](#)

#### General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

## ABSTRACT

Colorectal cancer (CRC) is the third most prevalent and second leading causes of cancer-associated deaths globally. Over the last few decades, *ent*-kaurane diterpenes have been widely investigated for their anticancer potentials. Flexicaulin A (**9**) is a naturally occurring *ent*-kaurane. Previously, our lab modified the structure of **9** by replacing the C-11 hydroxyl group with carbonyl group and obtained a novel compound oxoflexicaulin A (**11**). However, anticancer activities and mechanistic pathway of these two compounds are yet to be explored.

In the current thesis, we evaluated the cytotoxicity of compounds **9** and **11** in A549 lung, A375 melanoma, PANC1 pancreatic, HCT-116 and HT-29 colon cancer and 293T human embryonic kidney cells as well as compared the activity with a number of known natural *ent*-kauranes to describe their structure-activity relationship. Our study found that the presence of  $\alpha$ ,  $\beta$ -unsaturated ketone groups in *ent*-kaurane structure acted as the pharmacophore. The replacement of C-11 hydroxyl group by carbonyl in **9** (IC<sub>50</sub>: 3.68  $\mu$ M) gives a novel potent anticancer compound **11** (IC<sub>50</sub>: 0.77  $\mu$ M).

Considering the novelty and superior activity of **11**, its mechanistic pathway was studied in HCT-116 cells and compared with the natural scaffold **9**. Flow cytometry analysis by Annexin V/PI staining along with fluorescent staining by DAPI showed that both compounds induced apoptosis in HCT-116 cells. Induction of apoptosis is mediated through up-regulation of tumor suppressor protein p53 and pro-apoptotic protein Bax, Bak and puma as well as promoting the cleavage of PARP while down-regulation of anti-apoptotic protein Bcl-2 and PARP. Apart from their effect on apoptosis, compounds **9** and **11** stimulated the

event of senescence, a process of cellular aging, as confirmed by  $\beta$ -galactosidase assay. Induction of senescence is related with up-modulation of p21 and p27 while down-modulation of p16, Rb and its transcription factor E2F1. Moreover, immunofluorescence staining showed translocation of p21 and p27 from the cytoplasm to nucleus after treatment with **9** and **11**. Further study found that the two *ent*-kauranes inhibited the protein level of two NF- $\kappa$ B sub-units p65 and p50 in the nucleus as well suppressed the cytoplasmic level of NF- $\kappa$ B inhibitor I $\kappa$ B- $\alpha$ . Both compounds also inhibited the expression and phosphorylation of STAT3 in the cytoplasm and nucleus, so as for the expression and phosphorylation of Src, an up-stream kinase of STAT3.

In xenograft nude mice model, compound **11** remarkably inhibited tumor growths (volume and size) but the body weights of the mice were also reduced ( $p < 0.05$ ). Therefore, we designed to synthesis a series of prodrug analogs from **11** by adding acetal protecting group to reduce the toxicity. One of the prodrug (**37**) significantly attenuated the tumor volume and size ( $p < 0.05$ ) at 50 mg/kg without any toxicity ( $p > 0.05$ ). The prodrug **37** is actually released as compound **11** in the mice due to its cleavage in the acidic microenvironment of tumor. Taken together, antitumor effect of compound **11** in CRC model is supposed to be mediated through induction of apoptosis and senescence via modulation of NF- $\kappa$ B and STAT3 signaling pathway.

**Keywords:** Colorectal cancer, *ent*-kaurane, flexicaulin A, oxoflexicaulin A, cytotoxicity, anticancer, apoptosis, pathway, NF- $\kappa$ B, STAT3

## TABLE OF CONTENT

DECLARATION	i
ABSTRACT	ii
ACKNOWLEDGEMENTS	iv
LIST OF TABLES	xii
LIST OF FIGURES	xiii
LIST OF ABBREVIATIONS	xviii
<b>CHAPTER 1</b>	<b>1</b>
A LITERATURE REVIEW ON PLANT AS A SOURCE OF ANTICANCER AGENTS	1
Overview	2
1. Introduction	3
1.1 Colorectal cancer	4
1.1.1 Diagnosis and Staging of CRC	5
1.1.2 Current Therapies for CRC	10
2. Natural Products as a Source of Drugs	15
3. Plant as a Source of Anticancer Agents	17
3.1 Plant-derived Anticancer Agents in Clinical Use	18
3.2. Plant-derived Anticancer Agents at Development Stages	21
3.3. Plant-derived Anticancer Compounds at Experimental Stages and Mechanistic Pathways	27
3.3.1 Alkaloids	28
3.3.2 Flavonoids	37
3.3.3 Terpenes	50
3.3.4 Quinones	57
3.3.5 Phenolics	60

3.3.6 Xanthenes	67
3.3.7 Sulfur-Containing Compounds	68
3.3.8 Others	69
4. <i>ent</i> -Kaurane Diterpenes as a Source of Anticancer Agents	80
4.1. Anticancer <i>ent</i> -Kauranes and Their Targets	81
4.1.1. Oridonin	83
4.1.2. Eriocalyxin B	85
4.1.3. Excisanin A	87
4.1.4. Ponicidin	88
4.1.5. Pharicins A and B	88
4.1.6. Jaridonin	89
4.1.7. Jungermannenones A and B	90
4.1.8. Effusanin E	90
4.1.9. Longikaurin A	91
4.1.10. Glaucocalyxins A and B	92
4.1.11. Lasiodin	93
4.1.12. Adenanthin	94
4.1.13. Kaurenic acid	95
4.1.14. Weisiensin B	95
4.1.15. Inflexinol	96
4.1.16. Xerophilusin B	96
4.1.17. Henryin	97
4.1.18. Jolkinolides A and B	97
4.1.19. 11 $\alpha$ , 12 $\alpha$ -epoxyleukamenin E	98
4.1.20. DEK	99

4.1.21. JDA-202	99
4.1.22. Pterisolic acid G	100
4.1.23. Maoecrystal I	100
4.1.24. CHKA	101
4.1.25. CrT1	101
4.1.26. <i>Ent</i> -16 $\beta$ -17 $\alpha$ -dihydroxykaurane	102
4.1.27. <i>Ent</i> -11 $\alpha$ -hydroxy-16-kauran-15-one	102
4.1.28. Hydroxy-15-oxo-zoapatlin	103
5. Conclusions and Future Scopes	114
<b>CHAPTER 2</b>	115
HYPOTHESES OF THE STUDY	115
2.1. Rationale of the Study	116
2.2. Hypotheses of the Study	116
<b>CHAPTER 3</b>	117
STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF NATURAL ANTICANCER <i>ENT</i> -KAURENE DITERPENES	117
Overview	118
1. Introduction	119
2. Purpose of the Research	120
3. Materials and Methods	121
3.1 Preparation of Samples	121
3.2 Cell Line and Culture	122
3.3 Sulforhodamine B (SRB) Assay	122
3.4 Structure-Activity Relationship Study	123
4. Results	123

4.1. Cytotoxic Activity of <i>ent</i> -Kauranes	123
4.2. Structure-Activity Relationship Analysis	127
5. Discussion	129
6. Conclusion	131
<b>CHAPTER 4</b>	132
UNDERLYING CYTOTOXIC MECHANISM OF ACTION OF FLEXICAULIN A AND OXO-FLEXICAULIN A IN HCT-116 CELLS	132
Overview	133
1. Introduction	134
2. Purpose of the Research	135
3. Materials and Methods	136
3.1 Sulforhodamine B (SRB) Assay	136
3.2 Colony Formation Assay	137
3.3 Senescence Assay	137
3.4 Apoptosis Assay by PI/Annexin V Staining	138
3.5 Apoptosis Assay by DAPI Staining	138
3.6. Scratch Wound Healing Assay	139
3.7. Matrigel Chamber Invasion Assay	139
3.8 Extraction of Total Protein and Immunoblot Analysis	140
3.9 Subcellular Fractionation	141
3.10 Immunofluorescence Staining	141
3.11 Xenograft Studies	142
3.12 Statistical Analysis	143
4. Results	143
4.1. Effect of Compounds <b>9</b> and <b>11</b> on the Growth of HCT-116 Cells	143

4.2. Effect of Compounds <b>9</b> and <b>11</b> on the Colony Formation of HCT-116 Cells	144
4.3. Effect of Compounds <b>9</b> and <b>11</b> on the Expression of Proliferation Marker PCNA	145
4.4. Effect of Compounds <b>9</b> and <b>11</b> on Apoptosis	146
4.4.1. Apoptosis Assay by Flow Cytometry	146
4.4.2. Apoptosis Assay by DAPI Staining	148
4.4.3. Effect of Compounds <b>9</b> and <b>11</b> on Intrinsic Apoptotic Markers	149
4.5. Effect of Compounds <b>9</b> and <b>11</b> on Cellular Senescence	151
4.5.1. $\beta$ -galactosidase Staining Assay	151
4.5.2. Effect of Compounds <b>9</b> and <b>11</b> on Senescence Markers and Localization of p21 and p27	152
4.6. Effect of Compounds <b>9</b> and <b>11</b> on NF- $\kappa$ B Signaling Pathway	155
4.7. Effect of Compounds <b>9</b> and <b>11</b> on STAT3 Signaling Pathway	157
4.8. Effect of Compounds <b>9</b> and <b>11</b> on Migration of HCT-116 cells	160
4.9. Effect of Compounds <b>9</b> and <b>11</b> on Invasion of HCT-116 cells	160
4.10. Effect of Compounds <b>9</b> and <b>11</b> on Metastatic Markers	160
4.11. Effect of Compounds <b>11</b> on Tumor Growth in Nude Mice	161
5. Discussion	164
6. Conclusion	170
<b>CHAPTER 5</b>	173
DEVELOPMENT OF OXO-FLEXICAULIN A PRODRUGS AND THEIR ANTITUMOR EFFECTS IN NUDE MICE MODEL	173
Overview	174
1. Introduction	175
2. Purposes of the Research	176
3. Materials and Methods	177
3.1 Synthesis of New Derivatives of Compound <b>11</b> (33-47)	177



3.2 Sulforhodamine B (SRB) Assay	186
3.3 Xenograft Studies	187
4. Results	188
4.1. Cytotoxicity Study and Structure-Activity Relationship	188
4.2. Xenograft Studies	190
5. Discussion	192
6. Conclusion	193
<b>CHAPTER 6</b>	210
CONCLUSION AND FUTURE PERSPECTIVES	210
6.1. Conclusion	211
6.2 Novelty and Significance of the Work	212
6.3 Future Perspectives	213
6.3.1. To study the pharmacokinetics of compound <b>11</b> and its acetal derivatives	213
6.3.2. To evaluate the effect of compound <b>11</b> on inflammation-induced cancer	214
6.3.3. To develop compound <b>11</b> as DHFR antagonist for the treatment of cancer	215
References	217
Appendices	291
Publications	296
Conference abstract	297
Conference presentations	297
Curriculum vitae	298